Keeping an M&A score? Here's the Big Pharma lineup, pre-megadeal

With so much M&A in the air, the lineup of top pharma companies will no doubt rearrange. Pfizer ($PFE), for one, would regain the No. 1 spot if it succeeds in buying AstraZeneca ($AZN). Merck's ($MRK) consumer health deal and planned drug-brand sale, GlaxoSmithKline ($GSK) and Novartis' ($NVS) swap-and-shop--they'll all force a market-value shuffle. So just for the record, which are the top drugmakers by market value today? Johnson & Johnson ($JNJ) ($282.9 billion), Roche ($RHHBY) ($244.6 billion) and Novartis ($214.5 billion). Pfizer comes in fourth, with $191.2 billion. Report

Suggested Articles

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.